- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02360722
Improving Nutritional Status With Oral Nutritional Supplement in Chinese Elderly
30. november 2016 oppdatert av: Abbott Nutrition
This is a single- country, interventional, double-arm study involving Chinese Elderly subjects.
Studieoversikt
Status
Tilbaketrukket
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This study aims to understand the following:
- The effect of long-term Oral Nutritional Supplementation (ONS) on improving nutritional and health status in Chinese elderly.
- The impact of long-term ONS on health cost including both medical cost and social health care burdens.
- The impact of long-term ONS on life quality of the elderly. The study includes Screening Visit (Day -7~0), and Visit 1(Day 0) to Visit 7 (Day 168±3). Enrollment of anticipated 666 subjects, Male or female Chinese ages >= 60 years, to get 400 evaluable subjects.
Studietype
Intervensjonell
Fase
- Fase 4
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
60 år til 80 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Male or female Chinese ages >= 60 years.
- Subject is ambulatory.
- Subject with risks of malnutrition defined as DETERMINE score >=3
- Subject's BMI is below 28.
- Subject has experienced hospital stay or surgery within 6 months prior to enrollment;
- Subject if takes any medications for concomitant chronic diseases should be in stable dosage for at least 3 weeks.
- Subject plans to live in the community for more than 6 months after recruitment.
- Subject has voluntarily signed and dated an informed consent form, approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) prior to any participation in the study.
Exclusion Criteria:
- Subject has history of allergy to any ingredient in the study product
- Subject dislikes the experimental product
- Subject has been diagnosed with diabetes.
- Subject who has malignancy expected to receive chemotherapy/ radiotherapy scheduled during the study period,
- Subject has a life expectancy less than 6 months.
- Subject who has reported chronic liver disease or liver cirrhosis or liver failure or any liver diseases not suitable for the study as the study physician's opinion.
- Subject who has reported impacted renal function as eGFR < 30 mL/min/1.73 m2 or renal dysfunction severe greater than stage 4 or any other renal diseases not suitable for the study as the study physician' s opinion.
- Subject who has experienced fever or diarrhea within one week prior to enrollment.
- Subject who is expected to have scheduled major surgery during the study period.
- Subject who has physical disabilities such as loss of hand or foot or limbs or any other physical disability which may affect the muscle mass measurement by the opinion of the study physician.
- Subject has an implanted electronic device or orthopedic metal implantations, such as pacemaker, cardiac defibrillator, subcutaneous injection pump, or metal hip, metal knee joint, metal fracture internal fixation, etc.
- Subject who has active tuberculosis (TB), hepatitis, or HIV infection as self-reported at enrollment.
- Subject has severe dementia or delirium, brain metastases, eating disorder, history of significant neurological or psychiatric disorder, or other conditions that may interfere with study product consumption or compliance with study protocol procedures in the opinion of the principal investigator or study physician.
- Subject is drug addicted or alcohol addicted
- Subject has any other disease or situation who should not to participate in the study by the opinion of study physicians.
- Subject is participating in other clinical trials which are not approved by AN
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Oral Nutritional Supplement
ONS + Nutritional education
|
Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
Two nutritional education courses at baseline and 3 months after intervention
|
|
Annen: Control Group
Nutritional education only
|
Two nutritional education courses at baseline and 3 months after intervention
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change of body weight from baseline to the end of the study
Tidsramme: 24 weeks
|
24 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Total number of sick days due to Upper Respiratory Tract Infections (URTI)
Tidsramme: 24 weeks
|
24 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studiestol: Xianfeng ZHAO, MD, PhD, Abbott Nutrition R&D China
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. oktober 2016
Primær fullføring (Forventet)
1. juli 2017
Studiet fullført (Forventet)
1. desember 2017
Datoer for studieregistrering
Først innsendt
27. januar 2015
Først innsendt som oppfylte QC-kriteriene
6. februar 2015
Først lagt ut (Anslag)
11. februar 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
2. desember 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. november 2016
Sist bekreftet
1. november 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- BL26
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .